Skip to main content

Knight Jeff E.'s Form 4 filing

Crinetics Pharmaceuticals, Inc. (CRNX) · filed Jul 17, 2024

Accession no.
0000950170-24-084346
Filed
Jul 17, 2024
Trade date
Jul 15, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.49M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Knight Jeff E.CIK 0001881007Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 15, 2024Common StockMOption exerciseAcquired+17,499$23.98+$419,626.0270,079Direct
Jul 15, 2024Common StockMOption exerciseAcquired+2,887$20.02+$57,797.7472,966Direct
Jul 15, 2024Common StockMOption exerciseAcquired+5,687$19.64+$111,692.6878,653Direct
Jul 15, 2024Common StockSSaleDisposed−27,000$55.00−$1,485,00051,653Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 15, 2024Common StockMOption exerciseDisposed−17,499$0.00$0112,501Direct
Jul 15, 2024Common StockMOption exerciseDisposed−2,887$0.00$020,213Direct
Jul 15, 2024Common StockMOption exerciseDisposed−5,687$0.00$085,313Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)